Cancer Pain and Opioid Use Disorder


ABSTRACT

Opioid use disorder (OUD) is progressively acknowledged and co-present in patients with cancer. Sadly, OUD is not dealt with or dealt with effectively in oncologysettings In addition, patients with cancer-related pain dealt with with narcotic pain medications are at threat for nonmedical opioid use (NMOU). More than two-thirds of patients with advanced cancer havepain Both OUD and NMOU requirement to be concomitantly dealt with together with cancer-related pain management to prevent problems such as overdose. We examine the approach to recognizing and treating OUD and NMOU in patients with cancer and cancer-related pain.

Intro

Primum non nocere. It is unpleasant to believe that the medications, opioids particularly, suggested to relieve pain and suffering might unintentionally trigger more damage than excellent. Nevertheless, the damages brought on by improper opioid recommending have actually been well recorded in the noncancer population and help guide opioid recommending in patients with cancer. 1 Of the primary ethical concepts of medical care, regard for nonmaleficence can be especially difficult when the lorry of offering symptomatic relief for numerous patients brings the problem of addiction for some. On a national scale, reactions to the opioid epidemic recapitulate comparable stress and anxieties about handling pain in the face of substance use disorders. 2

Pain is extremely widespread in all patients with cancer (30% -50%); its existence is specifically pertinent for patients with advanced cancer (around 70%) managed mainly by medical
oncologists. 3 Provided the high life time frequency of substance use disorders, numerous patients who establish cancer will have a pre-existing opioid use disorder (OUD), and much more patients will be susceptible to nonmedical opioid use (NMOU) and other kinds of what has actually been called chemical coping. 4,5 Nonmedical opioid use includes a broad spectrum of nonprescribed opioid use that is especially pertinent for patients with cancer who likewise experiencepain The meaning originates from the US National Study on Drug Use and Health and consists of use of opioids without a prescription, use with a prescription however not as recommended, or use planned mainly for the functions of the experience of sensation brought on by opioids. 6 Constant with the increasing frequency of OUD in the basic population, an boost in opioid- associated deaths was observed in patients with cancer particularly from 2006 to 2016. 7 In addition, patients might establish OUD throughout or after their treatment for cancer. For that reason, screening, evaluations, and conversations about substance use ought to be regular and its management smooth provided the logistical subtleties of cancer care. 5

The co-emergence of cancer and OUD establishes from (1) patients with a history of OUD or other substance use disorders who establish cancer or (2) patients with cancer who establish OUD. The latter group stems from the iatrogenic advancement of OUD. Sadly, the iatrogenic contribution of opioid direct exposure to OUD and its etiology are not well comprehended. 8 Although iatrogenic advancement of OUD represents the minority of OUD, it definitely requires more research study. Even still, numerous patients taking opioids will not belong to either group however might be at high threat for NMOU, specifically provided the high frequency of psychosocial stress factors in patients with cancer.

Herein we examine strategies for the management of pain in patients with cancer and concomitant OUD, either preexisting or establishing while being dealt with for pain, and strategies for pain management in patients with cancer who are at high threat for NMOU.

Techniques

We carried out thorough searches of PubMed and Google Scholar for all pertinent publications about OUD, more particularly in patients with cancer pain, utilizing the following keywords: oncology, cancer, opioid, opioid crisis, pain, palliation, opioid misuse, dependence,opioid use disorder We focused mainly on the research studies that explained oncological pain along with opioid use and existing pharmacologic therapies to handle OUD. We left out abstracts, remarks, and non– English language short articles.

Screening for Aberrant Opioid Use

Clinical practice standard suggestions for active screening and tracking of opioid pain management are notably insufficient regardless of the value of opioids to reward cancer pain and the threat of aberrant use. 5 A detailed research study of pain management practices discovered that clinicians were less most likely to use urine toxicology screening while recommending opioids or refuse opioid prescriptions for patients with cancer vs noncancer patients. 9 The National Comprehensive Cancer Network (NCCN) suggests the use of Threat Examination and Mitigation Technique tools that have actually been put in location and are FDA authorized for individual opioid items. 10 The NCCN suggests utilizing state-run prescription drug tracking programs and that clinicians are informed on aberrant use behaviors. 10 Quickly, these consist of such behaviors as compulsive use and fixation, obvious yearnings, and loss of control, in addition to continued use regardless of damage. 11 In addition to patient education concerning opioid items and assessing therapeutic reaction to opioids, the NCCN likewise suggests assessing patients for threat aspects associated with opioid misuse/abuse/ diversion and trackingfor opioid misuse and abuse Screening tools are readily available for this function however are not particular to cancer-related pain management. 12 A history of illegal drug, alcohol, or substance dependence, in addition to a family history of substance abuse, shows greater threat of aberrantopioid use In addition, more youthful patients with a history of legal issues, imprisonment, or psychiatric disorders such as posttraumatic stress disorder, bipolar disorder, anxiety, and depression have an increased threat of aberrant opioid medication use. 12 The NCCN standard suggestions motivate patients with a history of addiction to be dealt with for cancer-related pain in coordination with an addiction expert. In addition, patients with high-risk aspects for opioid misuse gain from psychosocial education, assistance services, and cognitive behavior therapies that resolve analytical techniques and strategies to lower the effect of flexible threat aspects. 10 Clinicians ought to think about interdisciplinary cooperations, consisting of early recommendations to interventional pain professionals, to make the most of the use of nonopioid strategies for pain relief. Outpatient check outs ought to be regular, such as weekly, if possible, to lower the amount of recommended opioids at any provided time point.

Examination of Psychosocial Stress Factors

An international symptoms evaluation is important for thorough pain management due to the fact that depression, anxiety, and mental distress aggravate the seriousness, tolerability, and chronicity of viewedpain At the very same time, to be in pain is to be distressed, which might speed up or aggravateanxiety and depression Likewise, depression reduces pain tolerance. 13 Problems, consisting of modifications in patterns of sleep, cognition, personality, or other substance use disorders, are both causes and effects in this circular process that defines what has actually been called overall pain by palliative care creator Dame Cicely Saunders. 14-16 The function of structured sign evaluations is to untangle the bidirectional relationship in between uncomfortable conditions and mental health and recognize locations of dysfunction where intervention might reduce suffering.

Adequate management of OUD, in addition to cancer-related pain, needs proper attention to the constellation of concomitant neuropsychiatric symptoms (eg, depression, anxiety, sleeping disorders, cognitive disability) that typically accompanypain The American Society of Clinical Oncology and the NCCN have actually presented standard suggestions for screening and treatment of these symptoms. 10,17 Although concomitant psychiatric symptoms might ease off while effectively resolving pain, it is usually advised both are cured concomitantly. Psychoeducation contributes in assisting patients comprehend the relationships amongst pain, depression, sleeping disorders, and bad executive function, for example. Patients ought to have an concept of when they are experiencing anxiety, for example, in the setting of pain or by itself, to help with the administration of as-needed medications. In addition, clinicians who deal with cancer-related pain,
specifically in the setting of OUD, ought to be able to easily acknowledge affective disorders (eg, depression, anxiety) and cognitive disorders (eg, delirium). Diagnostic unpredictability and treatment uneasiness ought to be fulfilled with timely recommendation to mental health clinicians and sign professionals. Comprehensive screening tools can accelerate acknowledgment and treatment of these concomitant sign clusters.

Psychosocial screeners and multisymptom evaluation tools ought to be gathered concomitantly with opioid threat evaluation tools, such as the Opioid Threat Tool or the Screener Opioid Evaluation for Patients with Pain. 18,19 Mental distress, anxiety, and depression might be examined utilizing the Distress Thermometer and Issue List, the Edmonton Sign Evaluation Scale, or PROMIS (Patient-Reported Results Measurement Information System) steps. PROMIS steps can be used to evaluate numerouspsychosocial symptoms They are originated from tradition steps and are verified in cancersettings Sleeping disorders might be dealt with by questioning sleep health practices and evaluating for preliminary, middle, and terminal sleeping disorders patterns. Cognitive disability and delirium ought to be examined by several time point evaluations of awareness, orientation, and attention. A number of quick self-report and clinician-administered scales step attention and examine for cognitive disability. The evaluation of alcohol and other substance use disorders might be achieved utilizing PROMIS steps, and the CAGE (lower, upset, guilty, eye-opener) screener for alcohol use might be extended to consist of substance use. 20 In addition, well-performing shortened and single-item screeners are readily available for alcohol (Alcohol Use Disorders Recognition Test Intake) 21 and other drug 22 use, which can activate more screening with the complete Alcohol Use Disorders Recognition Test or recommendation to treatment.

Case Discussion

A 57-year-old guy is being dealt with for frequent little cell lung cancer with third-line chemotherapy. He keeps in mind increasing bony pain needing intensifying dosages of short-acting hydromorphone in addition to the extended-release morphine solution he is currently taking. In addition to pain from bony transition, he has different mental issues, such as anxiety (most likely sped up by shortness of breath), preliminary and terminal sleeping disorders, tiredness, and memory disability. His clinicians have actually ended up being disappointed with what appears to be irregular and extreme use of as-needed short-acting hydromorphone as he confessed taking more than recommended to help with sleep and anxiety.

The patient has no individual or family historyof drug use or alcoholism He rejects other considerable psychosocial stress factors aside from having lung cancer. Universal screening exposes the existence of partly dealt with pain, no proof of cognitive disability or delirium, a favorable urine drug screen for opioids, and the existence of serious sleeping disorders, anxiety, and depressive symptoms.

Nonmedical Opioid Use

The National Institute on Substance abuse specifies NMOU as “taking an opioid in a way or dosage besides recommended, taking somebody else’s prescription opioid, even if for a genuine medical factor, or taking prescription opioids for the sensations that it produces.” 23 Chemical coping and NMOU relate ideas. Chemical coping refers to the use of opioid medications to reward mental suffering or psychological distress. 24 It is a questionable term that was very first used to explained drug- looking for behaviors of patients with end-stage alcoholism. 25 This classification might be experienced as stigmatizing, and, for that reason, it might be more valuable and proper to address unsettled distress. Obviously, pain is totally associated to mental distress. Pain relief might relieve distress; for that reason, patients might use opioids in excess of what is required to reward pain if distress is likewise ameliorated vis-à-visopioid medication Education concerning proper use of opioids and appropriate screening for mental comorbidities are crucial concepts for resolving NMOU and chemicalcoping Nonmedical opioid use might happen as a kind of chemical coping or opioid use for other non–pain- associated factors. It might arise from opioid accessibility and absence of mental health resource or psychoeducation accessibility, and the existence of mental health preconception. Oversight of NMOU and chemical coping needs not just restricting opioid medication accessibility however likewise offering required psychoeducation, screening and triaging for psychosocial distress, and making nonstigmatizing mental health recommendations. In reality, evaluating for NMOU is an chance to evaluate psychosocial distress also.

The issue with NMOU is the improper use of possibly unsafe and addictive medication to suboptimally deal with mentalsymptoms Anxiety, depression, and sleeping disorders are more securely and efficiently dealt with with proper (non) psychopharmacologic representatives to target thosesymptoms This syndrome is more common amongst young, male patients with a history of alcohol use, drug use, and cigarette smoking. 26,27 Patients who quickly intensify the opioid dosage, often grumble of pain with strength of 10 of 10, or are at threat for chemical coping ought to be referred to a helpful care/ palliative care group for interdisciplinary management normally consisting of a pain management expert and therapists. Resolving the most important concern ought to help limitation chemical coping and NMOU. At other times, patients will have a recognized history of OUD, which might be exposed or establish while dealing with the tensions of cancer. By meaning, patients with OUD are at high threat for losing control of their opioid use and will have greater rates of other psychosocial aspects that usually make pain more serious, and they tend to be more intolerant of pain (this eases off to some level when they are dealt with for OUD), needing greater dosages of opioids for pain control. Patients with OUD ought to be dealt with for OUD while getting treatment for cancer-related pain. 28

In the event discussion, it is most likely that NMOU would ease off with psychoeducation and effectively resolving anxiety, depression, and sleeping disorders.

Opioid Use Disorder

An individual is specified as having an OUD when there is a pathologic pattern of behaviors associated to opioid use, which is a mix of cognitive, behavioral, and physiologic symptoms. 29 The individual continues substance use regardless of emerging substance- associated issues, which triggers considerable disability or distress. The complete diagnostic requirements are provided in Table 1 A patient need to satisfy at least 2 diagnostic requirements, and seriousness is stratified as moderate, moderate, or serious if they satisfy 2 or 3, 4 or 5, or more than 6, respectively. A constraint of these diagnostic requirements is that seriousness is based on frequency of requirements instead of on disability. An individual might satisfy 7 requirements (serious) yet have little practical disability, and somebody else might satisfy 3 requirements (moderate) and have considerable practical disability.

Tolerance or withdrawal (typically called physiologic dependence) might happen throughout the proper use of opioid therapies and ought to not be counted towards a diagnosis of OUD when opioids are used entirely under proper medical guidance. Due to the fact that numerous clinicians and patients are worried with the possibility of opioid dependence, this is an essential difference that is diagnostically pertinent. In addition, numerous patients show signs of pseudoaddiction, a term created in 1989 by Weissman and Haddox 30 to explain an “iatrogenic syndrome that imitates the behavioral symptoms of addiction” in patients with insufficient pain control. Although the presence of pseudoaddiction, as specified, is questionable, the idea stays present in the medical literature and appears to highlight a medically pertinent idea. These patients are normally determined by significant behaviors such as requiring particular opioids to treat their pain or other timeless signs of drug- looking for behavior, however these behaviors ought to stop when appropriate pain control is accomplished. For that reason, patterns of drug use, consisting of path of administration (intravenous or intranasal), frequency, disability (ie, social, individual, professional), and other substance use ought to be checked out.

A total history with required security information is required to amuse a diagnosis of OUD: a physical exam in addition to complete social and mental health histories ought to be obtained from the patient. 31 The physical exam might expose a patient in intoxication (confusion, miosis, hypersomnia, queasiness, bliss, irregularity, reduced pain understanding)or withdrawal Urine drug tests are required throughout preliminary and follow-up check outs to determine the type of opioid substance used and other comorbid substance use, in addition to to screen remission and upkeep. 32 In many locations it is now required to consist of urine screening for fentanyl, which is typically not consisted of in basic urine drug test batteries. 33 If the patient has a history of intravenous drug use, tests such as infectious screening (HIV, liver disease B, liver disease C) are advised; echocardiography to eliminate endocarditis ought to be bought for those with a history of bacteremia. 31

Intricate relentless opioid dependence (CPOD) can establish from long-lasting opioid dependence and shares numerous functions with OUD, consisting of the biological systems associated with UOD. Complex relentless opioid dependence establishes in the setting of opioid therapy that has actually not been effective however does not satisfy the requirements for OUD. It exists on a continuum in between easy physical dependence and OUD. Complex relentless opioid dependence ought to be thought about when long-lasting opioid use and tapering are noteffective Remarkably, CPOD might react to buprenorphine treatment, which can likewise be used in a persistent pain setting. Marking the diagnostic entity associated with inefficient or improper opioid use has underlying treatment ramifications. Generally, psychosocial aspects, along with nonpharmacologic management of pain, ought to be thought about in all cancer-related pain treatment plans.

Management of Opioid Therapies in Patients With Cancer Who Have OUD

Considered that around one-half of patients with cancer were recommended an opioid throughout the year of their preliminary diagnosis, safe and effective pain management requirements to be accomplished while thinking about the management of OUD. Although the focus of this evaluation is safe opioid recommending in patients with OUD, one may think about the phenomenon of opioid misuse as a continuum, with chemical coping, NMOU, or CPOD being an early phase of substance use disorders. 34,35 In the early phases when patients use opioids to reward anxiety, depression, or sleep disorders, these actions can typically be countered with caring use of motivational talking to to help them in acquiring insight into their behaviors and to properly treat their psychological distress. Early recognition is required. 35,36 The cancer setting (eg, type, phase) and whether the patient is being dealt with with alleviative intent contribute in forecast of continuous pain and concomitant neuropsychiatricsymptoms Although early recognition of pain, along with appropriate treatment strategies, are still vital, the concomitant factors to consider differ based on treatment setting. In the alleviative setting, the clinician might be most anxious about resolving cancer-related pain and OUD to help with adherence with anticancer treatments, whereas quality of life and sign management might be more focused on in the palliative setting.

In addition, nonpharmacologic steps ought to be set up simply as would be proper for a patient with cancer however without OUD. These methods consist of psychoeducation concerning
activity and resolving pain management strategies proactively, workout therapy as endured, mindfulness and stress decrease, group assistance activities, back control, acupuncture, yoga, and other multimodal integrative therapies, in addition to nonopioid analgesics such as nonsteroidal anti-inflammatory drugs, chosen anticonvulsants (eg, gabapentin and pregabalin), and chosen antidepressants (eg, duloxetine for peripheral neuropathy, amitriptyline for sleeping disorders and irritable bowel syndrome types of pain). 37-39 Regardless of the extensive use of medical marijuana in patients with cancer and its prospective use in resolving OUD, the proof base is doing not have, and, for that reason, medical marijuana can not be advised to balance out opioid- based medications for OUD (MOUDs). 40,41

Patients with continuous, without treatment substance use disorders need more complex care than can normally be supplied in an oncology setting without considerable interdisciplinary assistance. 42 The objective might be the arrangement of pain control while utilizing “damage decrease,” which suggests the greatest level of safeand effective care The top priorities of the damage decrease design of care for OUD are prevention of overdose and other effects of risky use (eg, mishaps, infections), increased control over use (ie, reducing the overall quantity used), and preventing diversion. 43 A week’s supply of opioid might be recommended, instead of 1 month, and regular urine screening might beused Interdisciplinary care is called for. In addition, people with a medical history of substance use disorder and those who are in recovery might provide a special obstacle. Worries of relapse when provided with an opioid for the treatment of cancer pain might lead the patient to decline these medications. Offered proof does not assistance an increased threat of relapse for patients dealt with with opioid analgesics who are preserved on medications for OUD. 44-46
Having thoughtful conversations about use of opioids, attempting nonopioid analgesics, utilizing interventional therapies, and integrating the patient’s sponsor or case supervisor can help provide effective relief while restricting the threat of relapse.

Presently, there are 2 evidence-based MOUDs: buprenorphine and methadone, which are likewise authorized for pain. 47,48 Buprenorphine functions as a partial mu receptor agonist with high affinity and sluggish dissociation and might speed up withdrawal as it might displace otheropioids It is integrated with naloxone in most solutions authorized for OUD, to prevent inhalation or injection use of the items. Methadone is a complete mu receptor agonist with a long half-life. Both medications blunt bliss, reduce yearning, and are medically safe. They lower threat of overdose, severe and persistent infections, and suicide. 49,50 In basic, patients with cancer have at least double the threat of suicide, however the threat ends up being exceptionally noticable with pain and the very first couple of weeks to months after diagnosis or other cancer-related crises. 51 Buprenorphine and methadone have various dosing schedules for OUD treatment and analgesia: for pain management, they are recommended at lower dosages numerous times daily, as opposed to once-daily dosing for OUD. Use of these medications to reward OUD is extremely controlled. Buprenorphine prescribers require to receive a Drug Enforcement Firm waiver with constraints on the number of patients to be registered in the center, whereas methadone upkeep treatment need to be administered in a federally authorizedtreatment program These constraints do not use to prescriptions planned to rewardpain There is a scarcity of proof concerning dual treatments for co-occurring OUD and cancerpain For that reason, in 2021, Merlin and associates 52 performed an online customized Delphi approach to establish agreement for handling cancer pain in patients with OUD from specialists in the discipline of hospice and palliative medicine, pain medicine,and addiction medicine Professionals concurred that nonopioid pharmacologic and nonpharmacologic treatments ought to be optimized prior to changes of MOUDs. The summary of the suggestion is highlighted in Table 2

In both cases, specialists concurred that it would be improper to change buprenorphine-naloxone to a methadone upkeep treatment program, and vice versa. Professionals recommended changing buprenorphine-naloxone to split dosages of methadone as proper due to viewed weaker pain control, although research study by Neumann and associates 53 has actually revealed both medications to be similarly analgesic when started in patients determined as being addicted to otheropioids Stopping OUD treatment entirely and beginning a complete agonist opioid was dissuaded.

Patients who are taking a complete agonist opioid to reward cancer pain however who likewise satisfy the requirements for OUD might gain from a switch to methadone or buprenorphine as a primary analgesictherapy Typically, patients hesitate to switch pain medications due to issues of insufficient pain control. It is necessary to assure patients that excellent options exist, and physicians ought to focus on resolving the patient’s pain management while likewise decreasing prospective negative impacts from complete agonist opioids and riskydrug use If the patient wants to think about buprenorphine, a low-dose initiation procedure can be carried out to prevent withdrawal symptoms. 54 Edens et al 47,55 provide their house buprenorphine initiation procedure, which has actually been revealed to decrease negative impacts and reach therapeutic dosages for both pain management and OUD by day 5 ( Table 3).

Regardless of the suggestion that patients with OUD and cancer-related pain continue taking MOUDs, there are scenarios in which the clinician might require to think about likewise recommending a complete opioid agonist (Sidebar). For patients currently developed on MOUDs, systems of tolerance and hyperalgesia might prevent appropriate analgesia from buprenorphine or methadone alone. 56 Unrestrained pain plays a substantial function in patients with OUD returning to or continuing opioid use. 46 Concurrent prescribing of a short-term complete agonist has actually been revealed to lower withdrawal and yearning, address pain effectively, and prevent patients from turning to illegally gotten opioids. 57 From a damage decrease viewpoint, caring, effective care through appropriate pain management reduces the dangers of without supervision opioid use.

Conclusion

Management of cancer-related pain in patients who have OUD or are at threat for OUD needs an individualized approach based on the patient’s substance use history and pain management requires. In addition to making an precise diagnosis of substance use disorder, a thorough evaluation and an understanding of opioid and MOUD therapies are required to provide appropriate patient- focusedpain management Clinicians ought to understand that opioids may be misused, either unintentionally (eg, for its hypnotic and anxiolytic impacts) or actively by those with substance use disorders; nevertheless, caring care and damage avoidance concepts will support the mindful use of opioid medications when nonopioid and nonpharmacologic options are insufficient.

Recommendations:

Dispute of Interests: No dispute of interest reported by authors. We have actually evaluated and authorized the manuscript as it is sent and have no dispute of interest to state. Furthermore, each author fulfilled each of the authorship requirements as mentioned in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals. We had several functions in composing the manuscript consisting of the conception, style, acquisition, analysis and analysis of the information. The information in the manuscript has actually not been released formerly and is not under factor to consider for publication in other places.

Author associations:

Amvrine Ganguly, MD 1, ¥; Marco Michael, MD 1, ¥; Simona Gorschin, MD 2; Kirk Harris, MD 3; and Daniel McFarland, DO 2,4

¥ co-first authors

1 Department of Psychiatry and Behavioral Sciences, State University of New York City Downstate Brooklyn

2 Department of Psychiatry and Behavioral Sciences, Lenox Hill Hospital, Northwell Health, New York City, NY

3 Department of Psychiatry, University of Rochester, Rochester, NY

4 Department of Medicine (DM), Lenox Hill Hospital, Northwell Health, New York City, NY

Contact Information:

Daniel C. McFarland, DO
Department of Psychiatry and Behavioral Sciences
Lenox Hill Hospital, Northwell Health
New York City, NY 10034.
Email: danielcurtismcfarland@gmail.com

Referrals

  1. Humphreys K, Shover CL, Andrews CM, et al. Reacting to the opioid crisis in The United States And Canada and beyond: suggestions of the Stanford-Lancet Commission. Lancet. 2022; 399( 10324 ):555 -604. doi:10.1016/ S0140-6736( 21 )02252-2
  2. Bates N, Bello JK, Osazuwa-Peters N, Sullivan MD, Scherrer JF. Depression and long-lasting prescription opioid use and opioid use disorder: ramifications for pain management in cancer. Curr Reward Options Oncol. 2022; 23( 3 ):348 -358. doi:10.1007/ s11864-022-00954-4
  3. van den Beuken-van Everdingen MHJ, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. High frequency of pain in patients with cancer in a big population-based research study in The Netherlands.Pain 2007; 132( 3 ):312 -320. doi:10.1016/ j.pain2007.08.022
  4. Volkow ND, Jones EB, Einstein EB, Wargo EM. Prevention and treatment of opioid misuse and addiction: an evaluation. JAMA Psychiatry. 2019; 76( 2 ):208 -216. doi:10.1001/ jamapsychiatry.2018.3126
  5. Carmichael AN, Morgan L, Del Fabbro E. Identifying and evaluating the threat of opioid abuse in patients with cancer: an integrative evaluation. Subst Abuse Rehabil. 2016; 7:71 -79. doi:10.2147/ SAR.S85409
  6. Ulker E, Del Fabbro E. Finest practices in the management of nonmedical opioid use in patients with cancer-relatedpain Oncologist. 2020; 25( 3 ):189 -196. doi:10.1634/ theoncologist.2019-0540
  7. Chino FL, Kamal A, Chino JP. Opioid- associated deaths in patients with cancer: a population based research study of the opioid epidemic over the previous ten years 2018. J Clin Oncol 2018; 36( suppl 30):230. doi:10.1200/ JCO.2018.36.30 _ suppl.230
  8. Beauchamp GA, Nelson LS, Perrone J, Lyons MS. A theoretical structure and classification to define the iatrogenic contribution of therapeutic opioid direct exposure to opioid caused hyperalgesia, physical dependence,and opioid use disorder Am J Drug Alcoholic Abuse. 2020; 46( 6 ):671 -683. doi:10.1080/ 00952990.2020.1778713
  9. Liebling D, Mehta N, Gulati A. Opioid screening practices in the cancerpain patient J Palliat Medication. 2019; 22( 1 ):10 -17. doi:10.1089/ jpm.2018.0168
  10. Dans M, Kutner JS, Agarwal R, et al. NCCN Standards( R) Insights: Palliative Care, Variation 2.2021. J Natl Compr Canc Netw. 2021; 19( 7 ):780 -788. doi:10.6004/ jnccn.2021.0033
  11. Kwon JH, Tanco K, Hui D, Reddy A, Bruera E. Chemical coping versus pseudoaddiction in patients with cancerpain Palliat Assistance Care. 2014; 12( 5 ):413 -417. doi:10.1017/ S1478951513001351
  12. Anghelescu DL, Ehrentraut JH, Faughnan LG. Opioid misuse and abuse: threat evaluation and management in patients with cancerpain J Natl Compr Canc Netw. 2013; 11( 8 ):1023 -1031. doi:10.6004/ jnccn.2013.0120
  13. Marazziti D, Castrogiovanni P, Rossi A, et al. Pain limit is loweredin depression Int J Neuropsychopharmacol. 1998; 1( 1 ):45 -48. doi:10.1017/ S1461145798001047
  14. Tang J, Gibson SJ. A psychophysical assessment of the relationship in between quality anxiety, pain understanding, and caused stateanxiety JPain 2005; 6( 9 ):612 -619. doi:10.1016/ j.jpain.2005.03.009
  15. Kroenke K, Wu J, Bair MJ, Krebs EE, Damush TM, Tu W. Reciprocal relationship in between pain and depression: a 12-month longitudinal analysisin primary care JPain 2011; 12( 9 ):964 -973. doi:10.1016/ j.jpain.2011.03.003
  16. Schneider E, Linden M, Weigmann H, et al. Early decrease in uncomfortable physical symptoms is associated with enhancements in long-lasting depression results in patients dealt with with duloxetine. BMC Psychiatry. 2011; 11:150.
  17. ASCO Standards: Screening, Evaluation, and Care of Anxiety and Depressive Symptoms in Grownupswith Cancer American Society of Clinical Oncology. Released 2014. Accessed Month, day 2022. https://bit.ly/3RUg060
  18. Butler SF, Budman SH, Fernandez KC, Fanciullo GJ, Jamison Registered Nurse. Cross-validation of a screener to forecast opioid misuse in persistent pain patients (SOAPP-R). J Addict Medication. 2009; 3( 2 ):66 -73. doi:10.1097/ ADM. 0b013e31818e41da
  19. Reyes-Gibby CC, Anderson KO, Todd KH. Threat for opioid misuse amongst emergency department cancerpatients Acad Emerg Medication. 2016; 23( 2 ):151 -158. doi:10.1111/ acem.12861
  20. Yennurajalingam S, Edwards T, Arthur JA, et al. Anticipating the threat for aberrant opioid use behavior in patients getting outpatient helpful care assessment at a thorough cancercenter Cancer. 2018; 124( 19 ):3942 -3949. doi:10.1002/ cncr.31670
  21. Bradley KA, DeBenedetti AF, Volk RJ, Williams EC, Frank D, Kivlahan DR. AUDIT-C as a quick screenfor alcohol misuse in primary care Alcohol Clin Exp Res. 2007; 31( 7 ):1208 -1217. doi:10.1111/ j.1530-0277.2007.00403. x
  22. Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. A single-question screening testfor drug use in primary care Arch Intern Medication. 2010; 170( 13 ):1155 -1160. doi:10.1001/ archinternmed.2010.140
  23. Prescription Opioids DrugFacts. National Institutesof Health Released June 2021. Accessed June 15, 2022. https://bit.ly/3Bbac1K
  24. Kwon JH, Hui D, Bruera E. A pilot research study to specify chemical coping in cancer patients utilizing the delphi approach. J Palliat Medication. 2015; 18( 8 ):703 -706. doi:10.1089/ jpm.2014.0446
  25. Strasser F, Walker P, Bruera E. Palliative pain management: when both pain and suffering hurt. J Palliat Care. 2005; 21( 2 ):69 -79.
  26. Nguyen LM, Rhondali W, De la Cruz M, et al. Frequency and predictors of patient discrepancy from recommended opioids and barriers to opioid pain management in patients with advanced cancer. J Pain Sign Manage. 2013; 45( 3 ):506 -516. doi:10.1016/ j.jpainsymman.2012.02.023
  27. Del Fabbro E. Evaluation and management of chemical coping in patients with cancer. J Clin Oncol. 2014; 32( 16 ):1734 -1738. doi:10.1200/ JCO.2013.52.5170
  28. Pergolizzi JV Jr, Magnusson P, Christo PJ, et al. Opioid therapy in cancer patients and survivors at threat of addiction, misuse or complicated dependence. Front Pain Res (Lausanne). 2021; 2:691720. doi:10.3389/ fpain.2021.691720
  29. American Psychiatric Association. Diagnostic and Analytical Handbook of Mental Illness. fifth ed. American Psychiatric Association; 2013.
  30. Weissman DE, Haddox DJ. Opioid pseudoaddiction: an iatrogenic syndrome.Pain 1989; 36( 3 ):363 -366. doi:10.1016/ 0304-3959( 89 )90097-3
  31. Dydyk AM, Jain NK, Gupta M.Opioid use disorder In: StatPearls [Internet]. StatPearls Publishing; 2022. Accessed March 7, 2022. https://bit.ly/3Owa6ou
  32. Johnson RE, Pressure EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend. 2003; 70( suppl 2): S59-S77. doi:10.1016/ s0376-8716( 03 )00060-7
  33. Dezman ZDW, Felemban W, Bontempo LJ, Dream ED. Proof of fentanyl use is common and often missed out on in a cross-sectional research study of emergency department patients in Baltimore, Maryland. Clin Toxicol (Phila). 2020; 58( 1 ):59 -61. doi:10.1080/ 15563650.2019.1605078
  34. Castaneda AM, Lee CS, Kim YC, Lee D, Moon JY. Resolving opioid- associated chemical coping in long-lasting opioid therapy for persistent noncancer pain: a multicenter, observational, cross-sectional research study. J Clin Medication. 2018; 7( 10 ):354. doi:10.3390/ jcm7100354
  35. Yennurajalingam S, Arthur J, Reddy S, et al. Frequency of and aspects associated with nonmedical opioid use behavior amongst patients with cancer getting opioids for cancerpain JAMA Oncol. 2021; 7( 3 ):404 -411. doi:10.1001/ jamaoncol.2020.6789
  36. Bruera E, Paice JA. Cancer pain management: safeand effective use of opioids Am Soc Clin Oncol Educ Book. 2015: e593-e599. doi:10.14694/ EdBook_AM.2015.35. e593
  37. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Effectiveness of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol. 2009; 15( 13 ):1548 -1553. doi:10.3748/ wjg.15.1548
  38. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating uncomfortable neuropathy, persistent pain or fibromyalgia. Cochrane Database Syst Rev. 2014( 1 ): CD007115. doi:10.1002/ 14651858. CD007115.pub3
  39. Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life amongst patients with chemotherapy-induced uncomfortable peripheral neuropathy: arandomized clinical trial JAMA. 2013; 309( 13 ):1359 -1367. doi:10.1001/ jama.2013.2813
  40. Wiese B, Wilson-Poe AR. Emerging proof for marijuana’ functionin opioid use disorder Marijuana Cannabinoid Res. 2018; 3( 1 ):179 -189. doi:10.1089/ can.2018.0022
  41. Suzuki J, Weiss RD. Cannabinoids for the treatment of opioid use disorder: where is the proof? J Addict Medication. 2021; 15( 2 ):91 -92. doi:10.1097/ ADM. 0000000000000711
  42. Kircher S, Zacny J, Apfelbaum SM, et al. Comprehending and treating opioid addiction in a patient with cancerpain JPain 2011; 12( 10 ):1025 -1031. doi:10.1016/ j.jpain.2011.07.006
  43. Taylor JL, Johnson S, Cruz R, Gray JR, Schiff D, Bagley SM. Incorporating damage decrease into outpatient opioid use disorder treatment settings: damage decreasein outpatient addiction treatment J Gen Intern Medication. 2021; 36( 12 ):3810 -3819. doi:10.1007/ s11606-021-06904-4
  44. Kantor TG, Cantor R, Tom E. A research study of hospitalized surgical patients on methadone upkeep. Drug Alcohol Depend. 1980; 6( 3 ):163 -173. doi:10.1016/ 0376-8716( 80 )90455-x
  45. Manfredi PL, Gonzales GR, Cheville AL, Kornick C, Payne R. Methadone analgesia in cancer pain patients on persistent methadone upkeeptherapy J Pain Sign Manage. 2001; 21( 2 ):169 -174. doi:10.1016/ s0885-3924( 00 )00252-9
  46. Karasz A, Zallman L, Berg K, Gourevitch M, Selwyn P, Arnsten JH. The experience of persistent serious pain in patients going through methadone upkeeptreatment J Pain Sign Manage. 2004; 28( 5 ):517 -525. doi:10.1016/ j.jpainsymman.2004.02.025
  47. Edens EL, Abelleira A, Declan B, Becker WC. You statepain I stateaddiction Let’s call the entire thing off. Psychiatric Times. Released November 9, 2020. Accessed March 7, 2022. https://bit.ly/3v8bN4T
  48. Hanna V, Senderovich H. Methadone in pain management: an organized evaluation. JPain 2021; 22( 3 ):233 -245. doi:10.1016/ j.jpain.2020.04.004
  49. Mooney LJ. Medication treatment for opioid use disorder decreases suicide threat. Am J Psychiatry. 2022; 179( 4 ):262 -263. doi:10.1176/ appi.ajp.20220173
  50. Wakeman SE, Larochelle MR, Ameli O, et al. Relative efficiency of various treatment pathsfor opioid use disorder JAMA Netw Open. 2020; 3( 2 ): e1920622. doi:10.1001/ jamanetworkopen.2019.20622
  51. Ahn MH, Park S, Lee HB, et al. Suicide in cancer patients within the very first yearof diagnosis Psychooncology. 2015; 24( 5 ):601 -607. doi:10.1002/ pon.3705
  52. Merlin JS, Khodyakov D, Arnold R, et al. Professional panel agreement on management of advanced cancer-related pain in peoplewith opioid use disorder JAMA Netw Open. 2021; 4( 12 ): e2139968. doi:10.1001/ jamanetworkopen.2021.39968
  53. Neumann AM, Blondell RD, Jaanimagi U, et al. An initial research study comparing methadone and buprenorphine in patients with persistent pain and coexistentopioid addiction J Addict Dis. 2013; 32( 1 ):68 -78. doi:10.1080/ 10550887.2012.759872
  54. Suen LW, Lee TG, Silva M, et al. Fast overlap initiation procedure utilizing low dosage buprenorphine for opioid use disorder treatment in an outpatient setting: a case series. J Addict Medication. Released online February 10, 2022. doi:10.1097/ ADM. 0000000000000961
  55. Becker WC, Frank JW, Edens EL. Changing from high-dose, long-lasting opioids to buprenorphine: a case series. Ann Intern Medication. 2020; 173( 1 ):70 -71. doi:10.7326/ L19-0725
  56. Alford DP, Compton P, Samet JH. Severe pain management for patients getting upkeep methadone or buprenorphinetherapy Ann Intern Medication. 2006; 144( 2 ):127 -134. doi:10.7326/ 0003-4819-144-2-200601170-00010
  57. Thakrar AP. Short-acting opioids for hospitalizedpatients with opioid use disorder JAMA Intern Medication. 2022; 182( 3 ):247 -248. doi:10.1001/ jamainternmed.2021.8111

Leave a Comment

Our trained counselors are here to help answer anything.

Have Questions?

Contact Us